SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (181)9/12/1997 10:21:00 PM
From: scaram(o)uche   of 1826
 
David:

OK, you can be a lunatic if you get him to change my focus to long-term with near-term enthusiasm.

53% (dry mouth), and my market figures are going up..........

Ryumachi 1997 Jun;37(3):453-457

Treatment with pilocarpine hydrochrolide for sicca
symptoms in Sjogren's syndrome.

Takaya M, Ichikawa Y, Yamada C, Hoshina Y, Horiki T, Uchiyama M

Department of Internal Medicine, Tokai University School of Medicine, Kanagawa.

We studied the efficacy of oral pilocarpine hydrochrolide (9 mg/day, three times daily) on sicca
symptoms in 21 patients with Sjogren's syndrome (SS) of the patients, 19 continued the treatment
for at least one month, and subjective improvement of dry mouth and dry eye was observed in 10
patients (53%) and 5 patients (26%), respectively. As adverse effects, diaphoresis was most
frequently recognized, but it was generally mild and tolerable. In the four patients who have been
taking pilocarpine for 12 months, any severe side effects have not been observed. Since the
incidences of clinical improvement of sicca symptoms and adverse effects were comparable with
the other studies reported from US or Europe, our treatment protocol using pilocarpine
hydrochrolide (9 mg/day) was considered as appropriate for Japanese SS patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext